Eventide Asset Management, LLC Cytokinetics Inc Transaction History
Eventide Asset Management, LLC
- $4.71 Billion
- Q1 2025
A detailed history of Eventide Asset Management, LLC transactions in Cytokinetics Inc stock. As of the latest transaction made, Eventide Asset Management, LLC holds 382,696 shares of CYTK stock, worth $14.2 Million. This represents 0.33% of its overall portfolio holdings.
Number of Shares
382,696
Previous 254,148
50.58%
Holding current value
$14.2 Million
Previous $12 Million
28.65%
% of portfolio
0.33%
Previous 0.23%
Shares
3 transactions
Others Institutions Holding CYTK
# of Institutions
400Shares Held
128MCall Options Held
3.66MPut Options Held
900K-
Black Rock Inc. New York, NY14.7MShares$546 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.8MShares$441 Million0.01% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD9.96MShares$370 Million0.26% of portfolio
-
Wellington Management Group LLP Boston, MA7.99MShares$297 Million0.06% of portfolio
-
State Street Corp Boston, MA6.09MShares$226 Million0.01% of portfolio
About CYTOKINETICS INC
- Ticker CYTK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,144,096
- Market Cap $3.5B
- Description
- Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...